title: Long-term Management of Moderate to Severe Plaque Psoriasis Patients With Etanercept: A Case Series.
abstract: BACKGROUND
  Currently, etanercept (ETN) safety and efficacy in patients with moderate to severe plaque psoriasis (PsO) has been reported up to 5 years.
  
  
  OBJECTIVE
  To present a case series of PsO patients receiving continuous ETN therapy for 7 or more years.
  
  
  METHODS
  Physicians collected data retrospectively from 52 patient charts from 5 centres across Canada.
  
  
  RESULTS
  Patients in this case series had PsO an average of 31.5 years. Nearly half of patients also had psoriatic arthritis (24/52). All patients demonstrated sustained improvement in Psoriasis Area and Severity Index (PASI) and percentage of affected body surface area (BSA) following ETN treatment. Of the 52 patients, 33 have been receiving ETN for 10 years or more.
  
  
  CONCLUSIONS
  The clinical experience described in this case series report suggests maintenance of ETN efficacy in PsO patients who receive therapy for 7 years or more and indicates that patients can be successfully managed with long-term ETN therapy.
authors.affiliation: Sherbrooke University, Sherbrooke, Canada mbourcier@rogers.com.
authors.forename: Marc
authors.initials: M
authors.lastname: Bourcier
authors.affiliation: K. Papp Clinical Research and Probity Medical Research, Waterloo, Canada.
authors.forename: Kim Alexander
authors.initials: KA
authors.lastname: Papp
authors.affiliation: Memorial University of Newfoundland, St. John's, Canada.
authors.forename: Wayne P
authors.initials: WP
authors.lastname: Gulliver
authors.affiliation: Centre dermatologique du Quebec metropolitain, Quebec, Canada.
authors.forename: Yves
authors.initials: Y
authors.lastname: Poulin
authors.affiliation: Dr Kirk Barber Dermatology, Calgary, Canada.
authors.forename: Kirk
authors.initials: K
authors.lastname: Barber
authors.affiliation: Amgen Canada Inc, Mississauga, Canada.
authors.forename: Melanie
authors.initials: M
authors.lastname: Poulin-Costello
authors.affiliation: Amgen Canada Inc, Mississauga, Canada.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Shelton
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D015331:Cohort Studies; D004334:Drug Administration Schedule; D000068800:Etanercept / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000068800:Etanercept
keywords: biologic; case series; case study; etanercept; long-term treatment; psoriatic arthritis